Result活動実績

List of Publications
論文発表(英文)

2021

  • Sato Y, Mori K, Hirano K, Yagi K, Kobayashi Y, Nagaoka K, Hosoi A, Matsushita H, Kakimi K, Seto Y. Adoptive γδT-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer. Cytotherapy. 2021 Mar 26:S1465-3249(21)00058-X. doi: 10.1016/j.jcyt.2021.02.002. Epub ahead of print. PMID: 33781711.
  • Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H. Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo. In Vivo. 2021 Jan-Feb;35(1):239-248. doi:10.21873/invivo.12252. PMID: 33402470.

2020

  • Yabuno A, Matsushita H, Hamano T, Tan TZ, Shintani D, Fujieda N, Tan DSP, Huang RY, Fujiwara K, Kakimi K, Hasegawa K. Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Sci Rep. 2020 Oct 28;10(1):18503. doi: 10.1038/s41598-020-75536-1. PMID: 33116254; PMCID:PMC7595156.
  • Nagaoka K, Shirai M, Taniguchi K, Hosoi A, Sun C, Kobayashi Y, Maejima K, Fujita M, Nakagawa H, Nomura S, and Kakimi K. Deep-immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. Journal for ImmunoTherapy of Cancer 2020 Oct;8(2):e001358. doi: 10.1136/jitc-2020-001358.
  • Sato Y, Wada I, Odaira K, Hosoi A, Kobayashi Y, Nagaoka N, Karasaki T, Matsushita H, Yagi K, Yamashita H, Fujita M, Watanabe S, Kamatani T, Miya F, Mineno J, Nakagawa H, Tsunoda T, Takahashi S, Seto Y, and Kakimi K. Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells. Clin. Transl. Immunol., 9: e1194. doi:10.1002/cti2.1194. PMID: 33101677.
  • Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment- refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. J Immunother Cancer. 2020 Sep;8(2):e001185. doi:10.1136/jitc-2020-001185. PMID: 32948652.
  • Kobayashi Y, Kushihara Y, Saito N, Yamaguchi S, Kakimi K. A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions. Cancer Sci. 2020 Aug 18. doi: 10.1111/cas.14621. Epub ahead of print. PMID: 32810311.
  • Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375.
  • Sugie T, Sato E, Miyashita M, Yamaguchi R, Sakatani T, Kozuka Y, Moritani S, Suzuki E, Kakimi K, Mikami Y, Moriya T. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Breast Cancer. 2020 Jul;27(4):519-526. doi: 10.1007/s12282-020-01110-2. Epub 2020 May 23.
  • Ma L, Sakamoto Y, Kanai A, Otsuka H, Takahashi A, Kakimi K, Imai T, Shimokawa T. Characterization of a Novel Murine Colon Carcinoma Subline with High-Metastatic Activity Established by In Vivo Selection Method. Int J Mol Sci. 2020 Apr 18;21(8):2829. doi: 10.3390/ijms21082829.
  • Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. Int J Oncol. 2020 Apr;56(4):999-1013. doi: 10.3892/ijo.2020.4975. Epub 2020 Feb 4.
  • Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K, Hayashi S, Maejima K, Nakano K, Fujimoto A, Ono A, Aikata H, Ueno M, Hayami S, Tanaka H, Miyano S, Yamaue H, Chayama K, Kakimi K, Tanaka S, Imoto S, Nakagawa H. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020 Mar;53:102659. doi: 10.1016/j.ebiom.2020.102659. Epub 2020 Feb 26.

2019

  • Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda M, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda M, Nozawa R, Kakimi K, Oka M. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. J Thorac Oncol. 2019 Dec;14(12):2071-2083. doi: 10.1016/j.jtho.2019.08.008. Epub 2019 Aug 23.
  • Sugimoto K, Kakimi K, Takeuchi H, Fujieda N, Saito K, Sato E, Sakamaki K, Moriyasu F, Itoi T. Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019 Jun;30(6):845-853.e6. doi: 10.1016/j.jvir.2019.03.002.
  • Nejo T, Matsushita H, Karasaki T, Nomura M, Saito K, Tanaka S, Takayanagi S, Hana T, Takahashi S, Kitagawa Y, Koike T, Kobayashi Y, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Narita Y, Nagane M, Ueki K, Nishikawa R, Aburatani H, Mukasa A, Saito N, Kakimi K. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunol Res. 2019 Jul;7(7):1148-1161. doi: 10.1158/2326-6066.CIR-18-0599. Epub 2019 May 14.
  • Aoki H, Ueha S, Shichino S, Ogiwara H, Hashimoto SI, Kakimi K, Ito S, Matsushima K. TCR Repertoire Analysis Reveals Mobilization of Novel CD8(+) T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration. Front Immunol. 2019 Jan 24;9:3185. doi: 10.3389/fimmu.2018.03185. eCollection 2018.

2018

  • Kawashima M, Sato M, Murakawa T, Anraku M, Konoeda C, Hosoi A, Kakimi K, Nakajima J. Role of Toll-like Receptor 4 Expressed by Fibroblasts in Allograft Fibrosis in Mouse Orthotopic Tracheal Transplantation. Transplant Proc. 2018 Dec;50(10):3863-3872. doi: 10.1016/j.transproceed.2018.06.023. Epub 2018 Jun 26.
  • Karasaki T, Qiang G, Anraku M, Sun Y, Shinozaki-Ushiku A, Sato E, Kashiwabara K, Nagayama K, Nitadori JI, Sato M, Murakawa T, Kakimi K, Fukayama M, Nakajima J. High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. J Thorac Dis. 2018 Aug;10(8):4741-4750. doi: 10.21037/jtd.2018.07.45.
  • Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, Kakimi K, Fujiwara K. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. 2018 May;15(5):6457-6468. doi: 10.3892/ol.2018.8101. Epub 2018 Feb 21.
  • Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, Saito T, Matsushita H, Uchida E, Seto Y, Goldenring JR, Kakimi K, Tatematsu M, Tsukamoto T. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 2018 May;109(5):1480-1492. doi: 10.1111/cas.13569. Epub 2018 Apr 15.
  • Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy. Sci Rep. 2018 Jan 18;8(1):1058. doi: 10.1038/s41598-018-19548-y.
  • Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, Arita J, Hasegawa K, Kakimi K, Kokudo N. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 2018 Jan 8;495(2):2058-2065. doi: 10.1016/j.bbrc.2017.12.083. Epub 2017 Dec 15.

2017

  • Nagaoka K, Hosoi A, Iino T, Morishita Y, Matsushita H, Kakimi K. Dendritic cell vaccine induces antigen-specific CD8 + T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. Oncoimmunology. 2017 Nov 20;7(3):e1395124. doi: 10.1080/2162402X.2017.1395124
  • Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology. 2017 Jun 16;6(8):e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017.
  • Ando K, Fujita H, Hosoi A, Ma L, Wakatsuki M, Seino KI, Kakimi K, Imai T, Shimokawa T, Nakano T. Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. J Radiat Res. 2017 Jul 1;58(4):446-455. doi: 10.1093/jrr/rrx005.
  • Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K. Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy. 2017 Apr;19(4):473-485. doi: 10.1016/j.jcyt.2017.01.002. Epub 2017 Feb 7.
  • Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J Thorac Oncol. 2017 May;12(5):791-803. doi: 10.1016/j.jtho.2017.01.005. Epub 2017 Jan 11.
  • Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing. Cancer Sci. 2017 Feb;108(2):170-177. doi: 10.1111/cas.13131. Epub 2017 Feb 9.

2016

  • Odaira K, Kimura SN, Fujieda N, Kobayashi Y, Kambara K, Takahashi T, Izumi T, Matsushita H, Kakimi K. CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential. Biochem Biophys Res Commun. 2016 Sep 23;478(3):1298-303. doi: 10.1016/j.bbrc.2016.08.115. Epub 2016 Aug 21.
  • Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in personalized cancer immunotherapy. Breast Cancer. 2017 Jan;24(1):16-24. doi: 10.1007/s12282-016-0688-1. Epub 2016 Mar 21.
  • Makise N, Morikawa T, Nakagawa T, Ichimura T, Kawai T, Matsushita H, Kakimi K, Kume H, Homma Y, Fukayama M. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma. Hum Pathol. 2016 Apr;50:62-9. doi: 10.1016/j.humpath.2015.11.007. Epub 2015 Nov 28.
  • Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2016 May;4(5):463-71. doi: 10.1158/2326-6066.CIR-15-0225. Epub 2016 Mar 15.

2015

  • Guidance Development Review Committee; Working Group for Clinical Studies of Cancer Immunotherapy; Working Group for Effector Cell Therapy; Working Group for CMC/Non-clinical Studies; Working Group for Cancer Vaccines and Adjuvants; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy; Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci. 2015 Dec;106(12):1761-71. doi: 10.1111/cas.12819.
  • Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. J Thorac Oncol. 2016 Mar;11(3):324-33. doi: 10.1016/j.jtho.2015.11.006. Epub 2015 Dec 29.
  • Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clin Cancer Res. 2015 Oct 1;21(19):4327-36. doi: 10.1158/1078-0432.CCR-15-0357.
  • Hirano K, Hosoi A, Matsushita H, Iino T, Ueha S, Matsushima K, Seto Y, Kakimi K. The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy. Oncoimmunology. 2015 Apr 1;4(8):e1019195. doi: 10.1080/2162402X.2015.1019195. eCollection 2015 Aug.
  • Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K. Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins. Bioconjug Chem. 2015 Oct 21;26(10):2076-84. doi: 10.1021/acs.bioconjchem.5b00328. Epub 2015 Sep 22.
  • Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K. Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor b (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient. PLoS One. 2015 Aug 20;10(8):e0136086. doi: 10.1371/journal.pone.0136086. eCollection 2015.
  • Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M, Fujii SI. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. Oncoimmunology. 2015 Jan 22;4(3):e995541. doi: 10.1080/2162402X.2014.995541. eCollection 2015 Mar.
  • Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, Shand FH, Kakimi K, Ito S, Matsushima K. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. Cancer Immunol Res. 2015 Jun;3(6):631-40. doi: 10.1158/2326-6066.CIR-14-0190. Epub 2015 Feb 20.

2014

  • Kakimi K, Matsushita H, Hosoi A, Miyai M, Ohara O. CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells. Oncoimmunology. 2014 Dec 3;4(3):e970464. doi: 10.4161/21624011.2014.970464. eCollection 2015 Mar.
  • Kakimi K, Matsushita H, Murakawa T, Nakajima J. γδ T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2014 Feb;3(1):23-33. doi: 10.3978/j.issn.2218-6751.2013.11.01.
  • Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y, Kakimi K. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer. 2014 Aug 19;2:30. doi: 10.1186/s40425-014-0030-4. eCollection 2014.
  • Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H, Abe Y, Kakimi K. Denatured mammalian protein mixtures exhibit unusually high solubility in nucleic acid-free pure water. PLoS One. 2014 Nov 18;9(11):e113295. doi: 10.1371/journal.pone.0113295. eCollection 2014.
  • Kobayashi T, Kakimi K, Nakayama E, Jimbow K. Antitumor immunity by magnetic nanoparticle-mediated hyperthermia. Nanomedicine (Lond). 2014 Aug;9(11):1715-26. doi: 10.2217/nnm.14.106.
  • Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. Mol Clin Oncol. 2014 Nov;2(6):1023-1027. doi: 10.3892/mco.2014.360. Epub 2014 Jul 29.
  • Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest. Cancer Immunol Res. 2015 Jan;3(1):26-36. doi: 10.1158/2326-6066.CIR-14-0098. Epub 2014 Aug 15.
  • Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y. High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol. 2014 Jan;2(1):38-42. doi: 10.3892/mco.2013.203. Epub 2013 Oct 18.
  • Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 2014 Apr;3(2):362-75. doi: 10.1002/cam4.196. Epub 2014 Feb 7.
  • Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017.
  • Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, Kakimi K, Kume H, Ishikawa S, Homma Y, Fukayama M. Prognostic significance of CD204-positive macrophages in upper urinary tract cancer. Ann Surg Oncol. 2014 Jun;21(6):2105-12. doi: 10.1245/s10434-014-3503-2. Epub 2014 Feb 4.
  • Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients. Vaccine. 2014 Feb 12;32(8):957-64. doi: 10.1016/j.vaccine.2013.12.042. Epub 2014 Jan 5.
  • Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells. Int J Cancer. 2014 Apr 15;134(8):1810-22. doi: 10.1002/ijc.28506. Epub 2013 Oct 21.

2013

  • Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor γ-chain and the common γ-chain. Cytotherapy. 2013 Apr;15(4):481-91. doi: 10.1016/j.jcyt.2012.12.004. Epub 2013 Feb 5.
  • Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells. Cancer Res. 2013 Jan 1;73(1):62-73. doi: 10.1158/0008-5472.CAN-12-0759. Epub 2012 Oct 29.
  • Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8竅コ T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013;9(7):e1003490. doi: 10.1371/journal.ppat.1003490. Epub 2013 Jul 11.

2012

  • Konoeda C, Koinuma D, Morishita Y, Sano A, Nagayama K, Motomura N, Kakimi K, Miyazono K, Nakajima J, Nicolls MR, Murakawa T. Epithelial to mesenchymal transition in murine tracheal allotransplantation: an immunohistochemical observation. Transplant Proc. 2013 Jun;45(5):1797-801. doi: 10.1016/j.transproceed.2012.11.024.
  • Dewi N, Yanagie H, Zhu H, Demachi K, Shinohara A, Yokoyama K, Sekino M, Sakurai Y, Morishita Y, Iyomoto N, Nagasaki T, Horiguchi Y, Nagasaki Y, Nakajima J, Ono M, Kakimi K, Takahashi H. Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent. Biomed Pharmacother. 2013 Jul;67(6):451-7. doi: 10.1016/j.biopha.2012.11.010. Epub 2012 Dec 26.
  • Kato Y, Kajiwara C, Ishige I, Mizukami S, Yamazaki C, Eikawa S, Kakimi K, Udono H. HSP70 and HSP90 Differentially Regulate Translocation of Extracellular Antigen to the Cytosol for Cross-Presentation. Autoimmune Dis. 2012; 2012:745962.doi: 10.1155/2012/745962. Epub 2012 Sep 25.
  • Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db.
  • Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15;132(2):345-54. doi: 10.1002/ijc.27682. Epub 2012 Jul 11.
  • Abe J, Ueha S, Yoneyama H, Shono Y, Kurachi M, Goto A, Fukayama M, Tomura M, Kakimi K, Matsushima K. B cells regulate antibody responses through the medullary remodeling of inflamed lymph nodes. Int Immunol. 2012 Jan;24(1):17-27. doi: 10.1093/intimm/dxr089. Epub 2011 Dec 20.

2011

  • Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K. Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp. 2011 Sep 9;(55):3182. doi: 10.3791/3182.
  • Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, Tomura M, Sugihara K, Takamura S, Kakimi K, Matsushima K. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med. 2011 Aug 1;208(8):1605-20. doi: 10.1084/jem.20102101. Epub 2011 Jul 25.
  • Toda M, Wang L, Ogura S, Torii M, Kurachi M, Kakimi K, Nishikawa H, Matsushima K, Shiku H, Kuribayashi K, Kato T. UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. Int J Cancer. 2011 Sep 1;129(5):1126-36. doi: 10.1002/ijc.25775. Epub 2011 Jan 12.
  • Yoshida Y, Nakajima J, Wada H, Kakimi K. γδ T-cell immunotherapy for lung cancer. Surg Today. 2011 May;41(5):606-11. doi: 10.1007/s00595-010-4478-7. Epub 2011 May 1.
  • Matsushita H, Kakimi K, Tomita Y, Tatsugami K, Naito S, Suekane S, Noguchi M, Moriya F, Matsuoka K, Itoh K, Kobayashi H, Eto M, Takahashi W, Kawano Y, Wada Y. Exploring immune therapy for renal cancer. Int J Urol. 2011 Jun;18(6):412-21. doi: 10.1111/j.1442-2042.2011.02762.x.
  • Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011 Dec 15;129(12):2836-46. doi: 10.1002/ijc.25955. Epub 2011 Mar 29.
  • Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδ Tcells: a phase I clinical study. J Immunother. 2011 Mar;34(2):202-11. doi: 10.1097/CJI.0b013e318207ecfb.

2010

  • Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010 May;37(5):1191-7. doi: 10.1016/j.ejcts.2009.11.051.
  • Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, Ueha S, Fujii S, Yamada H, Matsushima K, Moriyasu F, Kakimi K. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun. 2010 Feb 5;392(2):217-22. doi: 10.1016/j.bbrc.2010.01.019. Epub 2010 Jan 11.

2009

  • Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy. 2009;11(7):936-46. doi: 10.3109/14653240903219114.
  • Kimura K, Nagaki M, Saio M, Moriwaki H, Kakimi K. Role of CD44 in CTL-induced acute liver injury in hepatitis B virus transgenic mice. J Gastroenterol. 2009;44(3):218-27. doi: 10.1007/s00535-008-2300-8. Epub 2009 Feb 13.
  • Narui K, Noguchi N, Saito A, Kakimi K, Motomura N, Kubo K, Takamoto S, Sasatsu M. Anti-infectious activity of tryptophan metabolites in the L-tryptophan-L-kynurenine pathway. Biol Pharm Bull. 2009 Jan;32(1):41-4. doi: 10.1248/bpb.32.41.
  • Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer. 2009 Jul;65(1):1-8. doi: 10.1016/j.lungcan.2008.10.018. Epub 2008 Dec 4.

2008

  • Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842-56. doi: 10.1080/14653240802419328.
  • Kimura K, Nagaki M, Matsuura T, Moriwaki H, Kakimi K. Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury. Hepatol Res. 2009 Jan;39(1):93-105. doi: 10.1111/j.1872-034X.2008.00409.x. Epub 2008 Aug 19.
  • Saito A, Motomura N, Kakimi K, Narui K, Noguchi N, Sasatsu M, Kubo K, Koezuka Y, Takai D, Ueha S, Takamoto S. Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model. J Thorac Cardiovasc Surg. 2008 Jul;136(1):159-67. doi: 10.1016/j.jtcvs.2008.01.006. Epub 2008 May 22.
  • Hosoi A, Takeda Y, Furuichi Y, Kurachi M, Kimura K, Maekawa R, Takatsu K, Kakimi K. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization Cancer Res. 2008 May 15;68(10):3941-9. doi: 10.1158/0008-5472.CAN-08-0032.
  • Hosoi A, Takeda Y, Sakuta K, Ueha S, Kurachi M, Kimura K, Maekawa R, Kakimi K. Dendritic cell vaccine with mRNA targeted to the proteasome by polyubiquitination. Biochem Biophys Res Commun. 2008 Jun 27;371(2):242-6. doi: 10.1016/j.bbrc.2008.04.034. Epub 2008 Apr 28.
  • Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role of CD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008 Jun;48(6):952-61. doi: 10.1016/j.jhep.2008.01.033. Epub 2008 Mar 11.
  • Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N, Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008 Jun 15;111(12):5457-66. doi: 10.1182/blood-2008-01-136895. Epub 2008 Mar 28.

2007

  • Uno K, Hirosaki M, Kakimi K, Tominaga M, Suginoshita Y, Hasegawa G, Fukui M, Nakamura N, Shirakawa T, Kishida T. Impaired IFN-alpha production and the risk of cancer development. J Interferon Cytokine Res. 2007 Dec;27(12):1013-7. doi: 10.1089/jir.2007.0047.
  • Kurachi M, Kakimi K, Ueha S, Matsushima K. Maintenance of memory CD8+ T cell diversity and proliferative potential by a primary response upon re-challenge. Int Immunol. 2007 Jan;19(1):105-15. doi: 10.1093/intimm/dxl127. Epub 2006 Dec 6.

2006

  • Sasawatari S, Tadaki T, Isogai M, Takahara M, Nieda M, Kakimi K. Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. Immunol Cell Biol. 2006 Dec;84(6):512-21. doi: 10.1111/j.1440-1711.2006.01462.x. Epub 2006 Jul 20.
  • Matsuda Y, Toda M, Kato T, Kuribayashi K, Kakimi K. Fulminant liver failure triggered by therapeutic antibody treatment in a mouse model. Int J Oncol. 2006 Nov;29(5):1119-25.
  • Uno K, Suginoshita Y, Kakimi K, Moriyasu Y, Nakano K, Nakamura N, Fujita T, Horino Y, Sato T, Kishida T. Clinical utility of 2',5'-oligoadenylate synthetase activity measurement: using whole blood as a highly sensitive method to detect the effects of IFN. J Virol Methods. 2006 Sep;136(1-2):185-92. doi: 10.1016/j.jviromet.2006.05.005. Epub 2006 Jul 7.
  • Saito A, Motomura N, Kakimi K, Ono M, Takai D, Sumida S, Takamoto S. Cryopreservation does not alter the allogenicity and development of vasculopathy in post-transplant rat aortas. Cryobiology. 2006 Apr;52(2):251-60. doi: 10.1016/j.cryobiol.2005.12.002. Epub 2006 Jan 25.

2005

  • Uno K, Suginoshita Y, Kakimi K, Moriyasu F, Hirosaki M, Shirakawa T, Kishida T. Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma. World J Gastroenterol. 2005 Dec 14;11(46):7330-4. doi: 10.3748/wjg.v11.i46.7330.
  • Takai S, Kimura K, Nagaki M, Satake S, Kakimi K, Moriwaki H. Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice . J Virol. 2005 Dec;79(24):15142-50. doi: 10.1128/JVI.79.24.15142-15150.2005.
  • Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol. 2005 Aug;17(8):1023-34. doi: 10.1093/intimm/dxh284. Epub 2005 Jul 6.
  • Furuichi Y, Tokuyama H, Ueha S, Kurachi M, Moriyasu F, Kakimi K. Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J Gastroenterol. 2005 Jun 28;11(24):3772-7. doi: 10.3748/wjg.v11.i24.3772.
  • Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari FV. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology. 2005 Mar 15;333(2):293-300. doi: 10.1016/j.virol.2005.01.004.
ページの
先頭へ